BeiGene announced that the National Medical Products Administration of China has accepted the new drug application for tislelizumab, an investigational anti-PD-1 antibody, as a potential treatment for patients with relapsed/refractory classical Hodgkin’s lymphoma.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.